A patent approval in Canada for VAL001 fits well with the ongoing exit process, as North America is an important market for VAL001

With the progress since we started the exit process, especially in the last few months, we want to increase our capacity and strengthen our negotiating position, why Partner International with an established brand and network is a natural choice

We are very pleased to be representing Respiratorius. VAL001 is a very exciting breakthrough cancer therapeutic and we expect significant response from the industry. The excellent Phase I/II clinical trial results show the strong potential VAL001 has for Diffuse Large B-Cell Lymphoma.”

EMA's advice, that the next step is to directly initiate a Phase III study instead of first carrying out a Phase II study, means a repositioning for VAL001 and likely a reduction in development costs.

A patent approval in the US and Korea for VAL001 is of strength and with excellent timing for the ongoing exit-process as US is the single most important market for VAL001. The patent approval complements previously granted Orphan Drug Designation and further strengthens our market position

It is very honorable that the article was accepted after such a quick review which indicates great interest in our results.

The results of the clinical study are good, and I am still positive for major comparative studies

The new patent approval in Europe further strengthens the commercial value of RESP3000 and confirms that we have a strong patent application

A new patent approval in the Japan further strengthens patent protection for RESP3000, which is essential in all negotiations

A new patent approval in the US further strengthens patent protection for RESP3000 on the single most important market

A patent approval in Australia complements previous approvals in the United States and Israel and provides additional commercial value to the project